Perceptive Advisors LLC Acquires Shares of 3,162,529 BioCryst Pharmaceuticals, Inc. $BCRX

Perceptive Advisors LLC acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 3,162,529 shares of the biotechnology company’s stock, valued at approximately $24,668,000. Perceptive Advisors LLC owned about 1.50% of BioCryst Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC raised its position in shares of BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,267 shares during the last quarter. Focus Partners Wealth bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 2,115 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $81,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth $81,000. Institutional investors own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Evercore assumed coverage on BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 target price for the company. Needham & Company LLC dropped their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Finally, Wedbush dropped their target price on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.70.

BioCryst Pharmaceuticals Trading Up 0.3%

NASDAQ BCRX opened at $8.95 on Thursday. The stock has a 50-day simple moving average of $8.92 and a 200 day simple moving average of $8.16. The company has a market capitalization of $2.27 billion, a PE ratio of -5.03 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $10.32.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The company had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.20 EPS. As a group, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.